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hypoplastic left heart syndrome from stage I through Fontan
completion
Kirsten C. Odegard, MD,a David Zurakowski, PhD,a James A. DiNardo, MD,a Robert A. Castro, MT,a Francis X. McGowan,
Jr, MD,a Ellis J. Neufeld, MD,b and Peter C. Laussen, MBBSa,c934Objective: The risk for thrombosis is increased after the Fontan operation. It is unknown whether children with
univentricular heart disease have an intrinsic coagulation anomaly or acquire a defect in coagulation during the
course of the staged repair. This prospective, longitudinal study evaluated changes in coagulation profiles in a co-
hort of patients with hypoplastic left heart syndrome from stage I palliation through completion of the Fontan
operation.
Methods: Thirty-seven patients with hypoplastic left heart syndrome were enrolled prospectively, and the con-
centration of factors II, V, VII, VIII, IX, X, proteins C and S, fibrinogen, antithrombin, serum albumin, and liver
enzymes were measured before stage I palliation (mean age 4  2 days), before bidirectional Glenn (mean age
5.9  1.8 months), before the Fontan procedure (mean age 27.1  6.6 months), and after the Fontan procedure
(mean age 49  17.6months). Healthy children were used as age-matched controls for coagulation factors.
Demographic, hemodynamic variables, and elapsed time after the Fontan procedure were evaluated as possible
predictors of coagulation abnormalities.
Results: Significantly lower levels of both procoagulation and anticoagulation factors were demonstrated through
to completion of the Fontan procedure. After the Fontan procedure, there was a significantly higher factor VIII
level (P< .005) but no correlation with hemodynamic variables or liver function.
Conclusion: This longitudinal study in patients with identical cardiac disease and staged surgical procedures con-
firms the increase in factor VIII level after the Fontan procedure. This is an acquired defect, and although the cause
remains to be determined, monitoring factor VIII levels after the Fontan operation could indicate a subset of
patients at risk for thrombosis.As early outcome after the Fontan operation continues to im-
prove, the focus has changed from survival to long-term
morbidity, prognosis, and quality of life.1-3 A major factor
contributing to both early and late morbidity and mortality
after the Fontan operation is the potential for thromboem-
bolic complications.1,4,5 The incidence of thromboembolic
events in patients with Fontan physiology is uncertain but
has been reported to be as high as 20% to 33%.4, 6-9 The
etiology is not completely understood and is likely to be
multifactorial, including the nature of the Fontan circulation
with elevated central venous pressure, low flow with possi-
ble stasis through the atrial baffle and pulmonary circulation,
atrial dysrhythmias, ventricular dysfunction, hepatic dys-
function, and altered resting venous tone. It has also been
demonstrated that lower levels of both procoagulant and an-
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doi:10.1016/j.jtcvs.2008.09.031The Journal of Thoracic and Cardiovascular Suticoagulant factors precede the Fontan operation, and it has
been speculated that a ‘‘functional balance’’ may exist that
reduces the risk for thrombosis during the earlier staged pal-
liation for single ventricle cardiac defects.10,11
A possible hypercoagulable state after the Fontan proce-
dure predisposing to thrombus formation has been postu-
lated, secondary to low levels of the naturally occurring
anticoagulants protein C, protein S, and antithrombin,12,13
and elevation of factor VIII.14 Interpretation of these studies
is limited because they included heterogeneous patient
populations, often with various modifications of the Fontan
operation, and at a variable point in time after the Fontan
procedure.
The purpose of this single-center, prospective, longitudi-
nal study was to follow up a homogeneous cohort of children
with hypoplastic left heart syndrome (HLHS) undergoing
identical staged procedures from the Norwood operation to
after completion of the Fontan operation to determine
whether there may be an intrinsic or acquired anomaly in
the coagulation profile causing hypercoagulability in these
patients.
METHODS
After institutional review board approval and informed parental consent
had been obtained, 37 neonates with the diagnosis HLHS were enrolled in
this single-center prospective study. Patients were followed up from 1998 torgery c April 2009
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BDG ¼ bidirectional Glenn
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2006; patients were excluded if they had other known congenital abnormal-
ities or syndromes and had pre-existing or known family history of hemato-
logic disorder or coagulopathy.
All patients underwent identical staged surgical procedures. Neonates
underwent initial stage I palliation with a Norwood procedure using
a 3.5-mm polytetrafluoroethylene (Gore-Tex; W. L Gore & Associates,
Inc, Flagstaff, Ariz) right modified Blalock–Taussig shunt. The second
stage operation was a bidirectional Glenn cavopulmonary connection
(BDG) performed on cardiopulmonary bypass. The Fontan procedure con-
sisted of a fenestrated lateral tunnel, cavo–cavo–pulmonary connection, per-
formed with a 0.4-mm thickness polytetrafluoroethylene cardiovascular
patch and fenestrated with a 4-mm punch hole.
Postoperative and interstage anticoagulation management was at the dis-
cretion of each patient’s physician. Blood samples from all patients (7 mL)
were obtained the day of the operation before each stage (stage I, BDG, and
Fontan) after induction of general anesthesia and in the catheterization
laboratory after catheter placement for the post-Fontan evaluation. Those
patients receiving aspirin and/or warfarin sodium (Coumadin) as prophy-
laxis for thrombosis had these drugs withheld for an appropriate time period
before procedures. Hemoglobin, hematocrit, platelet count, prothrombin
time, and activated partial prothrombin time were measured immediately,
and this information was available to clinicians caring for the patients.
The remaining plasma was stored at70C in 200-mL aliquots for batch
analysis of the other coagulation assays; this information was not available
to clinicians during the admission of each patient. The circulating anticoag-
ulant factors measured were protein C, protein S, and antithrombin; the pro-
coagulant factors measured were II, V, VII, VIII, IX, X, and fibrinogen. All
samples were analyzed by identical techniques, in the same laboratory, and
by the same technician (R.A.C.); the techniques for analysis along with
coefficients of variation have been reported elsewhere.10,11,14
To determine whether the increase in factor VIII levels observed after the
Fontan operation could have been due to an acute inflammatory response,
we measured the level of von Willebrand factor post hoc in the available re-
maining frozen serum in 11 of the Fontan patients. An increase in both the
factor VIII and von Willebrand factor levels would be expected in an acute
phase response. vonWillebrand factor level was measured by a immunotur-
bidimetric assay of von Willebrand factor (STA-Liatest VWF:Ag kit; Diag-
nostica Stago, Asnieres France; coefficients of variation, 1.9% and 2.7%).
Because altered hepatic dysfunction can contribute to coagulation factor
abnormalities, serum alkaline phosphatase, gamma-glutamyl transferase,
alanine transaminase, aspartate transaminase, total bilirubin, albumin, and
total protein were measured in all patients and compared with normal values
for our laboratory.
Hemodynamic Variables
Ventricular, atrioventricular valve, and semilunar valve function was as-
sessed by 2-dimensional and Doppler echocardiographic examination for all
patients before data sampling. Cardiac catheterization was routinely per-
formed before the BDG and the fenestrated Fontan procedures, but not be-
fore the Norwood procedure in neonates. Catheterization data were also
available for all 20 of the post-Fontan patients. Data obtained at the time
of cardiac catheterization included superior vena cava oxygen saturation,
the ratio of pulmonary to systemic blood flow, superior vena cava pressure,
pulmonary artery pressure, pulmonary vascular resistance, and systemic
ventricular end-diastolic pressure. The time after the Fontan operationThe Journal of Thoracic andwas also examined as a potential variable contributing to coagulation abnor-
malities.
Age-Matched Control Coagulation Parameters
Developmental hemostasis, or maturation of the coagulation system in
infants and children, is widely recognized.15,16 To establish age-matched
reference ranges, we obtained informed written parental consent to draw
blood samples for coagulation factor assays in healthy infants and children
undergoing minor day surgery. We used published control values for neo-
nates because of a state of Massachusetts requirement limiting research in
newborn subjects unless potential direct benefit can be demonstrated by par-
ticipating in a clinical study. The available normative ranges for neonates
and infants vary according to the techniques and reagents used to measure
coagulation factor levels,15,16 and we chose to use the reference range de-
scribed by Andrew and associates16 because it provided values (mean age
2 days) with similar age distributions to our patients (mean age 2 days). Be-
yond neonates, there were a total of 90 control subjects, 30 for each age-
matched control group. The mean ages for the groups were 7.8  2.2
months, 26  12 months, and 8.3  2.9 years.
A total of 1.8 mL of blood was taken from each control patient, and after
centrifuge, the plasma was stored at70C for subsequent batch analyses in
the same laboratory using the techniques as described above. Normal ranges
in these age-matched control groups were based on the empirical 95% con-
fidence intervals and have been described in a previous manuscript.17
Because of technical problems, we were unable to obtain complete sam-
ples to measure prothrombin time and activated partial thromboplastin time
in all of the control patients, and to use a consistent reference range we chose
the range of normal for age as described by Andrew and colleagues.16
Statistical Analysis
Factor levels at each stage were compared with values from control pa-
tients by the 2-sample Student t test after verifying normality. Univariate
and multivariable logistic regression using maximum likelihood estimation
was performed to identify potential predictors of a coagulation abnormality.
Variables evaluated included age, weight, gender, systemic ventricular end-
diastolic pressure, superior vena cava oxygen saturation, superior vena cava
pressure, ratio of pulmonary to systemic blood flow, pulmonary artery pres-
sure, pulmonary vascular resistance, ventricular function, atrioventricular
valve regurgitation, and time after the Fontan operation. In comparing coag-
ulation factors between patients and age-matched controls, we used a 2-
tailed Bonferroni-adjusted P value of .005 as the criterion for statistical sig-
nificance inasmuch as there were 10 variables (P¼ .05/10¼ .005) provided
this conservative a-level was chosen to minimize the risk of type I (false
positive) errors.18,19 For those patients in whomwewere able to obtain com-
plete coagulation factor levels at each study point, a repeated-measures lin-
ear mixed model, with compound symmetry to model the covariance, was
applied to assess changes over time in coagulation variables from stage I
through post-Fontan completion. Statistical analysis was conducted with
the SPSS software package (version 6.0; SPSS Inc, Chicago, Ill).
RESULTS
The study population with the mean age and weight at the
time of each procedure is shown in Figure 1. Coagulation
factor analysis could not be performed in 1 of the patients
at the time of stage I, in 1 BDG patient, and in 1 post-Fontan
patient because of sampling error. In addition to death (n ¼
5) or heart transplantation (n ¼ 1), 11 patients were lost to
follow-up because they were out-of-state referrals who had
undergone the stage I palliation and/or BDG at our institu-
tion and subsequent procedures elsewhere. Post-Fontan pa-
tients were followed up at a mean of 27 17.8 months afterCardiovascular Surgery c Volume 137, Number 4 935
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the catheterization laboratory (n ¼ 16), a clinic visit (n ¼
2), in the operating room during a permanent pacemaker
placement (n¼ 1), or during a sternal wire removal (n ¼ 1).
Four neonates died while in the hospital after the Nor-
wood procedure, none as a result of acute thrombosis. The
coagulation factor levels in these 4 patients were similar to
the other patients before the Norwood procedure who sur-
vived to discharge. All survivors (89%) were discharged
home receiving aspirin as thrombosis prophylaxis.
There were no interstage deaths between the Norwood op-
eration and the BDG procedure. One patient was admitted to
the hospital with severe cyanosis at 2months of age, a throm-
bosed modified Blalock–Taussig shunt was diagnosed and
Stage I Norwood operation
n = 37
4 ± 2 days; 3.3 ± 0.5 kg
Died
4
LTFU
2
Pre-BDG 
n = 31
5.9 ± 1.8 months; 6.3 ± 1.2 kg
Died
1
OTx
1
LTFU
3
Fontan 
n = 26
27 ± 6.6 months; 11.3 ±1.3 kg
LTFU
6
Post Fontan 
n = 20
4.5 ± 1.7 years; 15.5 ±3.5 kg
FIGURE 1. Number of study patients, mean age and mean weight at each
stage LTFU, Lost to follow-up; BDG, bidirectional Glenn procedure; OTx,
orthotopic heart transplant.936 The Journal of Thoracic and Cardiovascular Surreopened by balloon dilation, and the patient was discharged
home receiving aspirin and warfarin; no coagulation factors
were measured at this admission.
All 31 patients who underwent the BDG procedure recov-
ered well and were discharged receiving aspirin for throm-
bosis prophylaxis. There was 1 interstage death between
the BDG and Fontan procedures. This patient died suddenly
at home at the age of 18 months. An autopsy failed to find
any particular cause of sudden death. One patient had severe
right ventricular dysfunction after the BDG procedure and
underwent successful heart transplantation.
All patients survived to discharge after the Fontan proce-
dure, and the fenestrations were open by echocardiography
at the time of discharge in all but 1 patient. The majority
of patients (22/26) were discharged receiving aspirin alone;
the other 4 patients were discharged receiving aspirin and
warfarin or aspirin and clopidogrel (Plavix). In 1 patient
a thrombus developed within the baffle, detected by echocar-
diography 2 months after the Fontan operation. The patient
was treated with warfarin and aspirin and the clot resolved.
Two patients needed cardiac transplantation after the Fontan
operation: both had failing Fontan physiology, and both suc-
cessfully underwent transplantation. The coagulation factor
levels in these patients were similar to those of the other
patients in the post-Fontan group.
Coagulation Factors
The comparison of coagulation factor levels between con-
trol subjects and all patients at each stage of surgical repair
and post-Fontan period are summarized in Table 1. Lower
concentrations of procoagulant and anticoagulant factors
are seen before each staged surgical procedure. Although
the levels of protein C and factors II, V, VII, and X remained
significantly lower than in the age-matched controls after the
Fontan operation (P<.005), the factor VIII level was signif-
icantly higher (P< .005), and 8 (42%) patients had factor
VIII levels greater than 160% activity (Figure 2); von Wil-
lebrand factor levels were not elevated in any of these 8TABLE 1. Comparison of coagulation factors for all patients with controls at each staged surgical procedure through to after Fontan completion
Variable
Stage I
(n ¼ 36) Controls*
Pre-BDG
(n ¼ 30)
Controls
(n ¼ 30)
Pre-Fontan
(n ¼ 26)
Controls
(n ¼ 30)
Post-Fontan
(n ¼ 19)
Controls
(n ¼ 30)
Fibrinogen (mg/L) 191  77y 270  54 210  71 251  68 302  84 276  53 336  93 279  61
Antithrombin (%) 34  12y 78  15 76  15y 106  13 93  13y 105  16 97  16 108  11
Protein C (%) 19  8y 43  11 43  14y 81  17 61  14y 98  20 58  15y 95  22
Protein S (%) 34  15y 63  15 77  19 89  20 76  23 86  15 80  22 87  16
Factor II (%) 39  14y 68  17 66  13y 90  12 79  13y 93  10 82  10 95  15
Factor V (%) 67  19y 98  18 80  16y 117  18 87  19y 109  16 71  17y 103  24
Factor VII (%) 33  13y 90  24 47  14y 88  20 57  15y 88  18 48  14y 92  27
Factor VIII (%) 57  22y 91  33 68  25 77  20 95  40 85  22 167  88y 96  32
Factor IX (%) 33  12y 51  15 54  22 66  15 63  14 69  11 71  18 80  21
Factor X (%) 34  10y 59  14 66  14y 95  14 74  14y 93  11 72  15y 90  17
*Published control values for neonates.16 yStatistically significant, P<.005 (Bonferroni criterion); n, number of patients who had blood samples drawn at each stage. Mean age for
pre-BDG controls 7.8  2.2 months, Pre-Fontan controls 2.6 12 months and post-Fontan controls 8.3 2.9 years. BDG, Bidirectional Glenn.gery c April 2009
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compared with controls are shown in Figure 3; 4 patients
had a protein C activity level less than 50%. No patient dem-
onstrated clinical evidence for a thromboembolic event, and
intracardiac thrombus was not detected by transthoracic or
transesophageal echocardiography on routine follow-up.
It was possible to collect a full coagulation profile at each
of the four stages of the study period in only 17 of the 37 en-
rolled subjects because of the limitations outlined above.
The changes in coagulation factor concentrations in these
17 patients over time are shown in Table 2. The change in
factor VIII concentration for these 17 patients is shown in
Figure 4; the increase in factor VIII levels after the Fontan
procedure was not related to the level before the Fontan op-
eration in these patients.
Hemodynamic variables and laboratory values at each
stage are shown in Tables 3 and 4. With the use of univariate
and multivariate logistic regression, no relationship was
demonstrated between significantly lower or higher factor
levels and gender, weight, hemodynamic variables, liver
function abnormalities, serum albumin, and the time interval
after the Fontan procedure (all P> .20).
DISCUSSION
This prospective, longitudinal study of coagulation pro-
files in a homogeneous cohort of patients with HLHS under-
going identical surgical procedures confirms the risk for
a significant increase in factor VIII level after the Fontan op-
eration and, in association with a significantly lower protein
C level, indicates an acquired prothrombotic risk in patients
with Fontan physiology.
The implications for thrombosis after the Fontan opera-
tion have been reported.1,3,5,20,21 du Plessis and coworkers5
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FIGURE 2. Factor VIII level in all study patients compared with age-
matched controls at each of the four stages. Before the Norwood operation,
patients had a factor VIII level significantly lower than controls. After the
Fontan operation, there was a significant increase in *factor VIII level (P<
.005).The Journal of Thoracic andreported an incidence of cerebral vascular accidents of 2.6%
in a cohort of 605 patients undergoing the Fontan procedure
between 1978 and 1993, although the cause of these events
could not be determined. The long-term survival, modes of
death, and predictors of mortality in 261 patients over a me-
dian follow-up of 12.1 years after the Fontan operation was
recently reported by Khairy and coworkers.3 A thromboem-
bolic event was deemed the cause of late death in 3% of
those patients who had survived the immediate perioperative
period after the Fontan operation, and it was the mode of
death in 25% of the patients who died. In this study, death
was considered thromboembolic in nature if thrombus was
identified either clinically or on autopsy within the systemic
venous or pulmonary artery circulation, but the frequency of
subclinical thrombus formation or systemic thromboem-
bolic events was not reported. In the studies by both du Ples-
sis and Khairy’s groups, anticoagulation practices were not
standardized.
Other retrospective cohort studies have also reported on
the frequency of thromboembolic events after the Fontan op-
eration. Coon and colleagues20 reported an incidence of
thromboembolic events in 8.8% of 592 patients who had un-
dergone a Fontan procedure. Anticoagulation practices were
not standardized, and they demonstrated that thrombus for-
mation occurred with equal frequency in all types of surgical
modifications to the Fontan procedure and occurred in the
Fontan pathway as well as the systemic venous atria. A re-
cent study by d’Udekem and associates1 of 305 patients
who had undergone the Fontan procedure in the current sur-
gical era with either an intracardiac or extracardiac lateral
tunnel technique reported a freedom from thromboembolic
events at 15 years after the Fontan procedure of 94.3%;
patients in this study who had a thromboembolic event did
so despite receiving warfarin for longer-term anticoagula-
tion. Kaulitz and coworkers21 reported an incidence of
7% of thrombotic events in 142 patients after the Fontan
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FIGURE 3. Protein C level in all study patients compared with age-
matched controls at each of the four stages. *Protein C was significantly
lower than in controls (P< .005).Cardiovascular Surgery c Volume 137, Number 4 937
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tion treatment.
Although evidence-based guidelines for anticoagulation
in children are available,22 there remains variability in
practice regarding the optimal long-term anticoagulation
prophylaxis after the Fontan operation.23 Jacobs and col-
leagues24 evaluated the efficacy of a strategy to reduce
thromboembolic events with aspirin alone, concluding that
more aggressive anticoagulation regimens seemed unwar-
ranted, at least on the basis of intermediate follow-up. Re-
cently, comprehensive guidelines for anticoagulation in
children recommended either aspirin or a vitamin K antago-
nist for longer-term management in children with Fontan
physiology.25 In our study, all patients after the Norwood
and BDG procedures, and 22 of the 26 Fontan patients,
were discharged home receiving aspirin prophylaxis as the
primary anticoagulation strategy. However, the decision
for longer-term anticoagulation therapy is influenced by
the anticipated risk for thrombosis, often based on the surgi-
cal technique, presence of arrhythmias, and a patient’s func-
tional status. However, it is also apparent that prophylactic
long-term anticoagulation does not necessarily mitigate the
risk for a later thromboembolic event in Fontan pa-
tients.1,3,26 Owing to the multiple factors contributing to
this risk, it is unlikely that a single therapy or drug will pro-
vide complete prophylaxis. Although needing further study,
it is possible that monitoring for an elevated factor VIII level
may provide a method to identify post-Fontan patients at risk
for thrombosis.
Abnormalities or an imbalance of both procoagulant and
anticoagulant proteins as a cause of a hypercoagulable state
in children who have previously undergone the Fontan oper-
ation have been described, including low levels of the natu-
rally occurring anticoagulants protein C, protein S, and
antithrombin,6-9 and more recently an increase in factor
VIII level.14,27 Interpretation from some of these studies is
limited, however, because subjects were studied at a single
TABLE 2. Coagulation factor levels (mean ± SD) over time for the
subgroup of 17 patients who had complete samples drawn at each stage
Variable Stage I Pre-BDG Pre-Fontan Post-Fontan
Fibrinogen (mg/L) 200.5  70 203.5  86 292.8  76 350.2  93
Antithrombin (%) 36.8  12 75.4  18* 93.1  16y 97.6  17
Protein C (%) 17.7  9 43.2  12* 60.2  16y 56.9  15
Protein S (%) 34.1  17 81.3  16* 71.1  18 76.3  19
Factor II (%) 37.5  14 64.7  15* 77.8  13 81.9  11
Factor V (%) 67.9  19 79.1  15 86.9  21 71.8  19
Factor VII (%) 32.7  14 49.3  13* 57.9  15 49.2  14
Factor VIII (%) 50.3  21 63.5  26 90.9  36 175.5  89z
Factor IX (%) 32.5  14 47.2  17 62.9  13 72.5  18
Factor X (%) 33.2  9 63.6  15* 71.5  13 72.4  16
Data are mean  SD. BDG, Bidirectional Glenn. The following symbols denote sig-
nificant changes (P< .005) between selected stages: *Stage I to pre-BDG; yPre-BDG
to pre-Fontan; zPre-Fontan to post-Fontan.938 The Journal of Thoracic and Cardiovascular Supoint in time, assay techniques were not controlled, and
age-matched controls were not used, which is particularly
important given the maturation of the hemostatic system
over the first several years of life.15,16,28 We10,11,14 ad-
dressed such limitations in our previous work in which we
reported changes in coagulation factors after staged surgical
palliation, but the subjects in these studies included hetero-
geneous diagnoses and had undergone different surgical
procedures.
Stage I Pre-BDG Pre-Fontan Post-Fontan
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FIGURE 4. Change in factor VIII concentration in the subgroup of 17 pa-
tients who were sampled at each of the four stages. The increase in factor
VIII level after the Fontan procedure was not related to the level before
the Fontan operation.
TABLE 3. Hemodynamic variables at each stage
Pre-BDG Pre-Fontan Post-Fontan
Echocardiography data
(n,%)
n ¼ 31 n ¼ 26 n ¼ 20
Ventricular function
Normal 22 (71%) 22 (85%) 17 (85%)
Mildly depressed 8 (26%) 4 (15%) 2 (10%)
Moderately–severely
depressed
1 (3%) 0 1 (5%)
AVVR
No regurgitation 15 (48%) 15 (58%) 8 (40%)
Trivial 13 (42%) 9 (35%) 10 (50%)
Mild–moderate 3 (10%) 2 (7%) 2 (10%)
Catheterization data
(mean  SD)
n ¼ 29 n ¼ 23 n ¼ 20
EDp (mm Hg) 9.1  3.1 9.9  2.9 8.2  1.9
SVCp (mm Hg) 7.5  2.8 13.2  3.3 13.0  3.8
TPG mmHg 4.9  2.4 4.9  2.7
PVR (Wood units) 1.8  0.8 1.9  0.8 1.6  0.7
Qp/Qs 1.2  0.4 0.7  0.1 0.8  0.1
PaO2 (mm Hg) 43.4  4.3 56.4  10.9 61.3  6.7
SvO2 (%) 50.5  7.7 61.0  11.3 65.5  5.7
SpO2 (%) 76.4  6.0 86.6  3.8 89.4  3.8
AVVR, Atrioventricular valve regurgitation; BDG, bidirectional Glenn; EDp, end-dia-
stolic pressure; PaO2, arterial oxygen tension; PVR, pulmonary vascular resistance;
Qp/Qs, pulmonary to systemic blood flow; SpO2, oxygen saturation; SvO2, superior
vena cava oxygen saturation; TPG, transpulmonary gradient.rgery c April 2009
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Stage I Pre-BDG Pre-Fontan Post-Fontan Normal range
Hematocrit (%) 39.7  5.8 41.0  3.9 39.9  3.4 39.8  4.0 33–55
Platelet (3103) 197.4  67.5 282  77.9 256  75.1 260  59.9 130–400
PT (s) 14.8  1.8 13.0  1.0 12.4  0.8 13.2  1.1 11.0–13.0
aPTT (s) 67.2  15.8 49.5  14.2 39.1  10.6 33.0  10.0 27–37
Albumin (g/dL) 2.8  0.5 3.3  0.4 3.6  0.4 3.9  0.5 3.0–4.6
AST (U/L) 45.4  40 31.9  13.4 37.6  20.1 38.0  11.0 2–40
ALT (U/L) 46.2  78.4 18.2  6.9 25.8  38.3 22.2  10.2 0–35
GGTP (U/L) 45.3 21.2 12.6  7.4 21.8  62.9 39.5  30.2 5–40
Bilirubin (mmol/L) 6.8  3.7 0.5  0.2 0.4  0.2 0.6  0.5 0.3–1.2
ALT, Alanine aminotransferase; AST, aspartate aminotransferase; BDG, bidirectional Glenn; GGTP, gamma-glutamyl transpepsidase; aPTT, activated partial thromboplastin time;
PT, prothrombin time.C
H
DThe advantage of this study, therefore, is the longitudi-
nal and prospective design that allowed observation of the
changes in coagulation factor abnormalities over time in
a consistent cohort of patients with the same diagnosis un-
dergoing identical procedures. Although significantly
lower levels of both procoagulant and anticoagulant fac-
tors were observed at all stages compared with those of
healthy controls, it appeared they matured over time in
a similar pattern to control subjects, albeit at a slower
rate. The maturation in coagulation factor levels is also
similar to the hemostatic maturation reported in patients
who have undergone a two-ventricle repair,17 which sug-
gests that the maturation of coagulation factors over time
is not specifically related to diagnosis. The conversion
from a state of relatively low factor VIII levels early in
the course of single ventricle palliation to an increase in
factor VIII level after the Fontan operation indicates an ac-
quired disturbance specifically related to the Fontan phys-
iology; the low von Willebrand factor levels measured in
the post-Fontan patients with elevated factor VIII levels
suggests that the increase in factor VIII was not an acute
phase response in these patients. There were no relation-
ships between factor levels and hemodynamic variables
at any of the stages in our study. In an earlier study,
we14 reported a correlation between increased central
venous pressure and an elevated factor VIII level in
post-Fontan patients, but we could not find any such
relationship in this longitudinal study. Hepatic synthetic
dysfunction (eg, reduced albumin) or evidence of hepato-
cellular dysfunction (eg, bilirubin, transaminase) did not
appear to be associated with coagulation abnormalities
either, an important observation given the prominent role
of the liver in the synthesis of procoagulants and anticoag-
ulants and the potential for altered liver blood flow and
oxygen delivery in these patients.
The importance of an elevated factor VIII level as an in-
dependent risk factor for both primary and recurrent venous
thrombosis in adult patients without cardiac defects has been
reported.29-31 Factor VIII levels greater than 150% are asso-The Journal of Thoracic and Cciated with a 5- to 6-fold increased risk for venous thrombo-
sis when compared with levels below 100%.32 Goldenberg
and coworkers33 reported that children with increased factor
VIII levels were also at increased risk for thrombosis. Ele-
vated factor VIII, D-dimer, or both at diagnosis of thrombo-
sis, and a persistent elevation in children with thrombosis
after standard-duration anticoagulant therapy, predicted
a poor outcome (ie, lack of thrombus resolution, recurrent
thrombosis, or development of a postthrombotic syndrome).
The cause of increased factor VIII levels in patients with
the Fontan circulation is unknown. Liver disease can be
associated with markedly elevated plasma factor VIII
levels,34,35 whereas the synthesis of many other coagulation
factors is reduced; it has been suggested that the increase
of plasma factor VIII concentrations may be due to up-reg-
ulation of factor VIII synthesis by inflamed liver sinusoidal
endothelium. The expression of factor VIII mRNA is partic-
ularly prominent in the endothelial lining of the liver sinu-
soids,36 and although speculative, it is possible that
patients with Fontan physiology may have chronically ele-
vated central and hepatic venous pressure, which could con-
tribute to an increase in factor VIII production from liver
sinusoidal endothelium. It has also been recently reported
that Fontan patients are at increased risk for liver fibrosis
and cirrhosis,37 although no relationship with factor VIII
levels was studied.
It is also important to note that the protein C levels were
significantly lower in our patients throughout the different
stages. Inasmuch as a high factor VIII level is an indepen-
dent risk factor for thrombosis in children and adults and
a low protein C level also predisposes for thrombosis, this
combination along with the Fontan physiology may place
these patients at a significantly higher risk for a thromboem-
bolic event.
There are limitations to our study because of sample size
and a relatively short follow-up time after the Fontan proce-
dure. Eleven patients were lost to follow-up. When design-
ing the study, we did not confine enrollment to patients
from our geographic area; however, if we had done so, theardiovascular Surgery c Volume 137, Number 4 939
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been higher. An elevated factor VIII level could be a marker
of risk for thrombosis, but we are unable to provide recom-
mendations for longer-term anticoagulation. A prospective,
randomized study treating post-Fontan patients who have an
elevated factor VIII level with or without longer-term antico-
agulation therapy is needed to answer this question. Al-
though we noted no clinical evidence for thrombosis in
our patients, we did not rule out the presence of intracardiac
thrombi with detailed examination such as that provided by
transesophageal echocardiography. Furthermore, measuring
changes in coagulation factors over time does not provide
a complete evaluation of risk for thrombus formation. We
did not perform specific platelet function studies nor assess
clot formation by thromboelastography. Finally, we did not
examine for specific coagulation protein polymorphisms
such as factor V Leiden; and it is unknown whether the fre-
quency of specific polymorphisms is increased in children
with congenital heart disease.
In summary, on the basis of the known risk for thrombo-
embolic events after the Fontan procedure, along with the in-
crease in factor VIII level demonstrated in this study and the
evidence that high levels of factor VIII may be an indepen-
dent risk factor for thromboembolic events, monitoring fac-
tor VIII levels may define a group of at-risk Fontan patients
who may benefit from long-term anticoagulation prophy-
laxis. Further work is necessary to determine whether there
may be a critical factor VIII level associated with thrombo-
embolic risk in these patients, and the interaction between el-
evated factor VIII levels and low levels of native circulation
inhibitors of coagulation, such as protein C or prothrombotic
genetic polymorphisms, contributing to thromboembolic
risk, needs to be determined.
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